Bondrix150 mg

Bondrix is a nitrogen-containing bisphosphonate used mainly for bone disorders in which bone breakdown (resorption) is excessive.

Established / FDA-approved uses

• Treatment of osteoporosis in postmenopausal women - to increase bone mineral density and reduce the risk of vertebral (spinal) fractures.
• Prevention of osteoporosis in postmenopausal women who are at risk of low bone mass.

Guideline-supported / commonly used indications

• Treatment and prevention of osteoporosis in men, and in glucocorticoid-induced osteoporosis, as guided by a physician (used based on clinical guidelines and local prescribing practice rather than a universal formal approval in every market).

Bondrix is not established for reversing severe bone loss on its own in every setting and is generally used together with adequate calcium and vitamin D intake, and lifestyle measures (weight-bearing exercise, smoking cessation), as advised by a physician.

Each formulation contains Ibandronic Acid (as ibandronate sodium) as the active ingredient.

• Oral tablet: commonly available as a 150 mg film-coated tablet (monthly dosing); other strengths (e.g. 2.5 mg daily tablets) exist in some markets.
• IV infusion: 3 mg/3 mL solution for intravenous injection, given every 3 months by a healthcare professional.

Tablets also typically contain standard excipients (e.g. lactose, microcrystalline cellulose, povidone, magnesium stearate, and a film coat) which do not affect the mechanism of action.

Bondrix is a third-generation, nitrogen-containing bisphosphonate that binds strongly to bone mineral (hydroxyapatite) and selectively inhibits osteoclast-mediated bone resorption, without directly interfering with bone formation.

It is used in the long-term management of osteoporosis to reduce bone loss, increase bone mineral density, and lower the risk of fragility fractures, particularly vertebral fractures, in postmenopausal women.

Bondrix is available as an oral, monthly tablet and as a quarterly intravenous infusion, giving patients and physicians a choice of route based on tolerability, adherence, and gastrointestinal risk factors.

Bondrix belongs to the bisphosphonate class of drugs, specifically a nitrogen-containing (aminobisphosphonate) agent used as a bone resorption inhibitor / anti-osteoporotic agent.

Ibandronic Acid works by binding to hydroxyapatite crystals in bone and being selectively taken up by osteoclasts, the cells responsible for bone resorption.

Inside osteoclasts, it inhibits the enzyme farnesyl pyrophosphate synthase in the mevalonate pathway, which disrupts the prenylation of small GTP-binding proteins essential for osteoclast function, cytoskeletal integrity, and survival. This leads to osteoclast inactivation and apoptosis, reducing bone turnover.

The net effect of Ibandronic Acid is decreased bone resorption relative to bone formation, resulting in a gradual gain in bone mineral density over months of therapy. It has high affinity for bone mineral, giving it a long duration of pharmacologic effect and allowing infrequent (monthly oral or quarterly IV) dosing.

Oral Bondrix must be taken on an empty stomach, first thing in the morning, with plain water only, followed by at least 60 minutes in an upright position before eating, drinking anything else, or taking other medicines — see Dosage and Administration for full details. The intravenous form is administered only by a healthcare professional in a clinical setting.

Calcium, antacids, and mineral supplements: Oral calcium, antacids, and supplements containing polyvalent cations (magnesium, aluminum, iron) significantly reduce absorption of oral Bondrix if taken together; separate these products from Bondrix by at least 60 minutes (ideally later in the day).

NSAIDs and aspirin: Concomitant use with NSAIDs may increase the risk of gastrointestinal irritation; use with caution, particularly with oral Bondrix.

Aminoglycosides: Both bisphosphonates and aminoglycosides can lower serum calcium; concurrent use may increase the risk of hypocalcemia and should be monitored.

H2-receptor antagonists: No clinically significant interaction or dose adjustment is required with H2-blockers.

Other oral medicines: Because of the strict fasting/upright requirement, other oral medicines should generally be taken after the 60-minute post-dose period to avoid reduced absorption of Bondrix or interference from co-administration.

Most patients tolerate Bondrix well. Reported side effects include:

Common

• Dyspepsia, nausea, abdominal pain, diarrhea or constipation
• Headache, dizziness
• Back pain, arthralgia (joint pain), myalgia (muscle pain)
• With the IV form: transient flu-like "acute phase reaction" (fever, myalgia, arthralgia) within the first few days after infusion

Less common but serious

• Esophagitis, esophageal ulcer, or esophageal erosion (oral form) - see Precautions and Warnings
• Osteonecrosis of the jaw - see Precautions and Warnings
• Atypical femoral fractures with long-term use - see Precautions and Warnings
• Severe musculoskeletal (bone, joint, or muscle) pain
• Hypersensitivity reactions, including rare anaphylaxis and severe skin reactions
• Hypocalcemia

Pregnancy: Bondrix is not indicated for use in women of reproductive potential or during pregnancy. Bisphosphonates are retained in bone for extended periods and released slowly over time, and animal studies have shown developmental toxicity. Bondrix should not be used in pregnancy; if pregnancy occurs or is planned, Bondrix should be discontinued and a physician consulted immediately.

Lactation: It is not known whether Bondrix is excreted in human breast milk. Because of the potential for adverse effects on the nursing infant and the drug's prolonged skeletal retention, Bondrix should not be used by breastfeeding women; a physician should be consulted regarding alternative options.

Esophageal and upper GI irritation (oral form)

Oral Bondrix can cause local irritation of the upper gastrointestinal mucosa. Esophagitis, esophageal ulcers, and erosions have been reported, especially in patients who do not follow the dosing instructions (remaining upright, taking with plain water, avoiding lying down). Patients who develop symptoms of esophageal irritation (difficulty or pain on swallowing, retrosternal pain, new or worsening heartburn) should stop Bondrix and seek medical advice.

Osteonecrosis of the jaw (ONJ)

Osteonecrosis of the jaw, presenting as delayed healing after dental extraction or jaw surgery, has been reported with bisphosphonates, including Bondrix, most often in patients with cancer receiving high-dose intravenous bisphosphonates, but also rarely in patients treated for osteoporosis. A dental examination with appropriate preventive dentistry is recommended before starting Bondrix in patients with risk factors (e.g. planned invasive dental procedures, poor oral hygiene, concomitant chemotherapy or corticosteroids).

Atypical femoral fractures

Atypical, low-trauma or spontaneous fractures of the femoral shaft have been reported with long-term bisphosphonate use, including Bondrix. New thigh, hip, or groin pain during treatment should be evaluated promptly. Periodic re-evaluation of the need for continued therapy is recommended, particularly after 3-5 years of use.

Renal impairment

Bondrix is not recommended in patients with severe renal impairment (creatinine clearance below approximately 30 mL/min) due to lack of clinical experience; use with caution and appropriate monitoring in mild-to-moderate renal impairment.

Hypocalcemia and mineral metabolism

Correct hypocalcemia and other disturbances of bone/mineral metabolism (e.g. vitamin D deficiency) before starting Bondrix. Adequate calcium and vitamin D intake should be ensured throughout treatment.

Musculoskeletal pain

Severe and occasionally disabling bone, joint, or muscle pain has been reported; if this occurs, discuss with a physician whether to continue treatment.

Acute phase reaction (IV form)

Transient fever and flu-like symptoms may occur after the first IV infusion; this usually resolves within a few days and lessens with subsequent doses.

Overdose of Bondrix, particularly of the oral form, may cause hypocalcemia, hypophosphatemia, and upper gastrointestinal irritation (esophagitis, gastritis, ulceration). No specific antidote is available.

If overdose is suspected, seek immediate medical attention or contact emergency services / a poison control center. Milk or antacids containing calcium or magnesium may be given orally to bind the drug if the overdose was oral and recent, and the patient should be kept upright to reduce esophageal irritation. Management should occur under direct medical supervision; do not attempt to treat an overdose at home without professional guidance.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children. The IV injection/infusion should be stored according to the specific product label and handled by healthcare professionals.

Elderly

No dose adjustment is generally required based on age alone; Bondrix is commonly used in elderly patients, who should be monitored for renal function and calcium status.

Renal impairment

No dose adjustment is needed in mild-to-moderate renal impairment; Bondrix is not recommended in severe renal impairment (see Precautions and Warnings).

Hepatic impairment

No dose adjustment is required, as Bondrix is not significantly metabolized by the liver; however, formal studies in hepatic impairment are limited.

Pediatric patients

Safety and efficacy of Bondrix have not been established in children and adolescents; it is not recommended for use in this population outside specialist supervision for specific rare bone conditions.

Bondrix is typically used long-term for osteoporosis management, often for several years, with periodic reassessment by the physician (commonly after 3-5 years) to weigh continued benefit against the small but increasing risk of atypical femoral fractures and osteonecrosis of the jaw with prolonged use. The physician may consider a "drug holiday" or continued therapy based on individual fracture risk.

Bisphosphonate (nitrogen-containing); anti-resorptive / anti-osteoporotic agent

Ibandronic Acid inhibits farnesyl pyrophosphate synthase in the osteoclast mevalonate pathway, preventing prenylation of GTP-binding proteins required for osteoclast cytoskeletal function and survival, which leads to osteoclast inactivation and apoptosis and a net reduction in bone resorption.

Category C (FDA legacy pregnancy category) - not indicated for use in pregnancy

The safety and efficacy of Bondrix have not been established in pediatric patients. It is not approved or generally recommended for routine use in children or adolescents. Use in pediatric bone disease is limited to specialist settings for specific rare conditions and is outside standard osteoporosis labeling.